ADVANCIS ANNOUNCES RESULTS OF PHARYNGITIS STUDY

Advancis Pharmaceutical announced that the company's Amoxicillin Pulsys Phase III clinical trial for the treatment of children with pharyngitis/tonsillitis due to Group A streptococcal infections (commonly referred to as strep throat) failed to achieve its desired microbiological and clinical endpoints. The trial compared Advancis' Amoxicillin Pulsys 775 MG or 475 MG "sprinkle" dosed once-daily for seven days to an oral suspension of 10 milligrams per kilogram of penicillin VK dosed four times daily for 10 days.

According to top-line trial data received today, Amoxicillin Pulsys failed to demonstrate statistical non-inferiority to the comparator therapy in the primary endpoint - bacterial eradication at the post-therapy test-of-cure visit for patients who successfully completed the trial protocol. As previously announced June 15, Advancis' adult Amoxicillin Pulsys product also failed to show statistical non-inferiority to its comparator therapy.